Although the incidence of IDH mutations is uncommon in NSCLCs, considering the high prevalence and low survival rate of lung cancer in China and worldwide, tumors‐harboring IDH mutations need further investigation for the subsequent development of novel therapeutic strategies. This evidence concerns the gene IDH2 and lung cancer.